PolandPoland

Study: Polish biotechs prepared to grow

19.09.2009

Kraków – The Polish biotechnology market has been shrinking in the last two years, according to a report just released by the Kraków-based consultancy PMR. Polish biotech industry sales fell by 2% in 2008 to PLN607m (EUR173m) compared to the year before, according to “Biotechnological innovations in the pharmaceutical industry”. But innovative projects that are currently in the start-up phase, says the report, could make Poland a growth cluster soon, with annual growth rates of up to 30% by 2011. “In our opinion, despite the lamentable global economic situation, Poland has a chance to develop a real biotechnological industry in the short term,” said the authors of the study, pointing out that EU funds such as the “Innovative Economy Operational Programme” have created new financial resources for R&D worth EUR120m that will pay off soon for Polish companies active in the field of red biotech. The report describes the top institutes as well as the young biotechs driving the positive expectations, among them Celther (stem-cell therapy), Celon Pharma (siRNA-based therapy), Mabion (modified monoclonal antibody therapy), Euroimplant (tissue engineering and regenerative medicine) and Biocontract (vaccines for skin and kidney cancer).

PolandPoland

07.03.2012

Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...

PolandPoland

01.03.2012

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...

PolandPoland

31.01.2012

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...

PolandPoland

10.12.2011

Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...

PolandPoland

09.12.2011

Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...

PolandPoland

01.10.2011

Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...

PolandPoland

02.08.2011

Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...

PolandPoland

12.06.2011

Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...

PolandPoland

12.06.2011

Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...

PolandPoland

11.06.2011

Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-poland/article/study-polish-biotechs-prepared-to-grow.html

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF27.5%
  • BB BIOTECH140.45 EUR6.3%
  • HBM86.00 CHF3.7%

FLOP

  • MOLOGEN7.85 EUR-17.4%
  • WILEX2.36 EUR-15.7%
  • MEDIGENE4.48 EUR-12.5%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR185.1%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-67.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014


Current issue

All issues

Product of the week

Products